Although this is significant, it is important to note that degarelix, the GnRH antagonist, was a new drug during the study period with strict prescription guidelines that tailored the drug to specific PCa population (ie, to those with preexisting CVD). Here, GNRH1 is linked to posterior cortical atrophy.